Pertussis surveillance in Sweden with enhanced follow-up of cohorts immunized with acellular pertussis vaccines
General pertussis vaccination was reintroduced in Sweden in January 1996 following the completion of a number of clinical trials and the subsequent licensure of acellular DTP-vaccines.
As a complement to the routine notification of pertussis in Sweden, enhanced surveillance of laboratory-confirmed pertussis started in October 1997. Gothenburg and surrounding municipalities were primarily not included due to independent follow-up.
Primary aims:
- To study the long-term effectiveness of acellular pertussis vaccines in conjunction with the reintroduction of pertussis vaccination in Sweden.
- To document any changes in strain characteristics of clinical isolates from recipients of specific pertussis vaccines.
Secondary aim:
- To collect background data for timing of possible later booster dose(s).
The results for 1997 – 2007 are presented in the ten-year-report. In addition a slide set presents the 10 y clinical epidemiology.
Technical details of person-time estimations are given in Appendix 1. Two separate Appendices 2 give areas specific post-licensure follow-up for GSK and Sanofi-Pasteur MSD vaccines, respectively.
A separate technical report presents ten-year of pertussis surveillance in the Göteborg area, including enhanced surveillance from 2003 - 2007.
Note: The data suggest progressive underreporting of cases with increasing age and number of doses. Traditional estimates of effectiveness will be inflated as compared to vaccine efficacy estimates obtained in randomised placebo controlled trials. Therefore, data from the present surveillance scheme should only be used for an overall assessment of changes in pertussis incidence after reintroduction of pertussis vaccine, and do not permit comparisons between vaccines. See full text for other caveats.
Uppdaterad 2011-11-04 11:45